Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. - Wikidata - awgldk - TriplyDB

Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.

Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.

http://www.wikidata.org/entity/Q34086841

about

Regulation of ovarian cancer stem cells or tumor-initiating cells The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer Notch signaling in serous ovarian cancer.Notch3 and HEY-1 as prognostic biomarkers in pancreatic adenocarcinoma.The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma.Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry.Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma NOTCH3 is a prognostic factor that promotes glioma cell proliferation, migration and invasion via activation of CCND1 and EGFR.Notch3 overexpression promotes anoikis resistance in epithelial ovarian cancer via upregulation of COL4A2.Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.WMAXC: a weighted maximum clique method for identifying condition-specific sub-network.Clinical Significance of NOTCH1 and NOTCH2 Expression in Gastric Carcinomas: An Immunohistochemical Study.Suppression of cancer stemness p21-regulating mRNA and microRNA signatures in recurrent ovarian cancer patient samples.NOTCH3 Is Induced in Cancer-Associated Fibroblasts and Promotes Angiogenesis in Oral Squamous Cell Carcinoma.Role of the DLL4-NOTCH system in PGF2alpha-induced luteolysis in the pregnant rat Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach.Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy.A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype Breaking through an epigenetic wall: re-activation of Oct4 by KRAB-containing designer zinc finger transcription factors.Integrative network analysis to identify aberrant pathway networks in ovarian cancer Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer The Notch signaling pathway as a mediator of tumor survival Functional redundancy of the Notch pathway in ovarian cancer cell lines.Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.Identification of the NAC1-regulated genes in ovarian cancer The role of Notch and gamma-secretase inhibition in an ovarian cancer model NOTCH2 expression is decreased in epithelial ovarian cancer and is related to the tumor histological subtype.Targeting SALL4 by entinostat in lung cancer.Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.Notch3 signaling-mediated melanoma-endothelial crosstalk regulates melanoma stem-like cell homeostasis and niche morphogenesis.Recently identified drug resistance biomarkers in ovarian cancer.The role of Notch signaling in the mammalian ovary.Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.

P2860

Q26853096-95DD7B1B-5A1E-438D-AF8A-C47EE80AB896 Q27008375-FE37CD1B-20F9-49B5-AD75-6B6438E6CF93 Q28540634-89868744-D808-4894-9A66-26DC44449267 Q30410019-2C0A778E-A23D-48AB-B039-A11CE0822FDA Q33798364-65407F9A-7C1D-4FDF-8FE4-353758F676CC Q33851035-72CD5AD0-F3A3-4D96-AA5C-3E573B888F8F Q34193222-A6F66329-1EFE-4ECB-BA5C-C354FAED313A Q34428162-93C5D7E7-4B56-42CE-95D8-683FA9EB34DD Q34491211-D6B109D0-C740-4079-8458-92E39B1B64B1 Q34506739-D8CEAD02-76AC-4717-B862-0B99A1074FB4 Q34612059-BB8457D7-2455-4958-BF6B-FF13C69E65E1 Q34794876-D2785B84-2DD0-4BD9-9D02-900E8C2286F8 Q34899256-F1113B56-17F7-4E39-A32A-3BF5D3E51964 Q35021721-F3ED0337-9949-4B63-81F7-F917A0F091C7 Q35033660-89E7FFE7-EE95-49F2-A3A2-D6C1285DBC63 Q35196364-64D1FDE5-7EAC-43B3-966A-D25B35E3A9F4 Q35229964-DF6D794A-2288-4E5C-9D44-BE29FD47977E Q35522043-CE55A748-DBB3-45A0-B12A-B284B4BDB92D Q35772988-9B1189F2-55F9-4391-8E48-859D17CFC0AF Q36001853-EE4E5CD6-C65A-4EA9-9729-3CCB7B2547E7 Q36072089-3A11F276-221C-4233-9B71-009D8BC1A1CE Q36230572-C881EDA6-9980-4459-AB33-BB914C139B47 Q36378255-DF587343-CF04-41D3-BF01-AB7E5AB95A17 Q36545528-2FD881CA-329F-49E0-BE29-7ED3CF1EE3BC Q36669986-94D44D7C-EDA7-4883-9179-4FE1E68C2A0C Q36716928-25FC5B77-F91E-4FC8-89CD-CB6B5B783EDA Q36746274-93EE2C16-32DA-4A51-9328-2455D75508EF Q36775333-D446EEF5-9DC9-4E92-BCAC-82F8F41924CB Q36971953-BAD50799-BFFE-41E1-9C08-46E891831A8A Q37289384-37D27DA9-F84C-49AD-AFD7-2BC6249371DA Q37381585-F2D1F2DB-48CA-4E13-B30A-E8C71AB281C2 Q37415453-9CD3B888-BF51-4E73-87A6-7D501F2B3CD0 Q37486241-673ECF4B-E9C4-42E0-B8C7-927E7F0B2974 Q37684455-BBB1BBBD-89DE-49DF-8742-7BDDE76BE949 Q37688956-FD57FF1D-6A50-4E2C-A12F-841CB167A7FC Q38046424-76C1251E-FC64-43EF-8ED0-E85EF39BED7C Q38717772-584C3248-F4BC-4444-B420-5FF7AFD71731 Q38741073-B6AB4D16-046A-4344-9686-3E11AC4D5940 Q38747422-2A38AE1E-33C8-42B4-B132-B07F62DA3D58 Q38832323-6CDEB394-F311-486F-ABCC-359BF162D7C5

P2860

Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.

http://www.wikidata.org/entity/Q34086841

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@ast

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@en

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@nl

type

label

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@ast

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@en

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@nl

prefLabel

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@ast

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@en

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@nl

P1433

Q34086841-719B10F9-C5F1-490F-9FFD-613E8BF99ACE

P1476

Q34086841-1052F60F-DD13-4682-84CB-C58379673B1B

P2093

Q34086841-01D4F67A-5941-4EB5-8C25-5422FB4067DE

Q34086841-083FEDA6-82A1-4C79-8A13-82B7C01B251F

Q34086841-2E2B5056-7F72-401F-B74B-14691AE27987

Q34086841-6421C78A-8D2D-4229-A5DD-75D576CB03DB

Q34086841-95E8D872-EB71-48AB-A54F-C710E15DDA75

Q34086841-F3482197-8553-4EBC-AF94-B8DEFA294A7D

P2860

Q34086841-02CB6788-697E-494D-BE55-480C1EECE19C

Q34086841-031D976A-DBD9-49F0-9AA1-B1E9E14E2C96

Q34086841-1320054B-0355-4175-BF31-0569D55E4B62

Q34086841-1B20ECCA-6B47-4887-8627-EA08CC97B2E6

Q34086841-26BE2B1F-E586-4AE7-ABA4-E5A7C8184E66

Q34086841-32D11446-662E-4F7A-874D-807A8A230EB6

Q34086841-3D2BC77A-7FF1-4AF9-B81D-E6CDA48DD694

Q34086841-3D3D3723-51DC-4D52-9F60-5CAD01D6B35F

Q34086841-410BA064-DCF7-4F7B-97CB-F7AC1BC381C5

Q34086841-5CF4C062-E59D-4B13-A30E-F1A4A16A791F

P304

Q34086841-26C89D96-2749-4B64-A3EB-F33F9A86C55B

P31

Q34086841-27503BC3-D75C-466C-A6B8-F0BD4809BEF8

P356

Q34086841-BDEA2438-704B-4E5E-998C-CA313E23A160

P407

Q34086841-F0D24419-9BB4-4566-BA02-514C38353288

P433

Q34086841-1D471563-EBED-4B58-A6E8-FFBC1681C12D

P478

Q34086841-1C9494A4-28EC-4389-87F5-B7E8D59F0975

P577

Q34086841-F8C3D67F-3866-4C4B-8DB8-B39CFB9C1A09

P5875

Q34086841-6D6EAD45-BC61-48ED-A2A0-55D607034CD2

P698

Q34086841-84FC2A28-EAB5-46C7-B906-43B25C3E2C1D

P921

Q34086841-106968D8-88BA-4BAC-A649-D9128CF4BB79

Q34086841-9DB55E84-AF12-49E2-89F8-E429C5DA6C86

P932

Q34086841-253604B6-3EA8-4AEB-B724-A64A5A444022

P356

AJPATH.2010.100316

P1433

The American Journal of Pathology

P1476

Notch3 overexpression is relat ...... ers resistance to carboplatin.

@en

P2093

Ben Davidson

http://www.w3.org/2001/XMLSchema#string

Claes G Tropè

http://www.w3.org/2001/XMLSchema#string

Ie-Ming Shih

http://www.w3.org/2001/XMLSchema#string

Joon Tae Park

http://www.w3.org/2001/XMLSchema#string

Tian-Li Wang

http://www.w3.org/2001/XMLSchema#string

Xu Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival

Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma

The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells

A protein interaction network for pluripotency of embryonic stem cells

Multiple molecular mechanisms for multidrug resistance transporters

Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma

Cancer statistics, 2009

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Identifying tumor origin using a gene expression-based classification map.

Notch signaling, gamma-secretase inhibitors, and cancer therapy.

P304

1087-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2353/AJPATH.2010.100316

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45423998

http://www.w3.org/2001/XMLSchema#string

P698

20671266

http://www.w3.org/2001/XMLSchema#string

P921

P932

2928943

http://www.w3.org/2001/XMLSchema#string